vs
CoStar Group（CSGP）与QuidelOrtho Corp（QDEL）财务数据对比。点击上方公司名可切换其他公司
CoStar Group的季度营收约是QuidelOrtho Corp的1.3倍（$899.9M vs $699.9M），CoStar Group净利率更高（5.2% vs -104.7%，领先109.9%），CoStar Group同比增速更快（26.9% vs -3.7%），CoStar Group自由现金流更多（$101.3M vs $-94.7M），过去两年CoStar Group的营收复合增速更高（17.1% vs -2.9%）
CoStar Group是1987年成立的美国商业地产服务商，总部位于弗吉尼亚州阿灵顿，业务覆盖北美、欧洲地区，为商业地产行业提供信息、分析及营销解决方案，旗下运营CoStar线上数据库、新闻网站及Apartments.com、Homes.com等多个线上平台。
奎德尔奥索公司是美国的诊断医疗产品制造商，旗下产品面向全球市场销售，深耕体外诊断领域，为医疗机构及相关用户提供专业的检测解决方案，助力全球医疗健康服务效率提升。
CSGP vs QDEL — 直观对比
营收规模更大
CSGP
是对方的1.3倍
$699.9M
营收增速更快
CSGP
高出30.6%
-3.7%
净利率更高
CSGP
高出109.9%
-104.7%
自由现金流更多
CSGP
多$196.0M
$-94.7M
两年增速更快
CSGP
近两年复合增速
-2.9%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $899.9M | $699.9M |
| 净利润 | $46.5M | $-733.0M |
| 毛利率 | 78.6% | — |
| 营业利润率 | 5.5% | -100.7% |
| 净利率 | 5.2% | -104.7% |
| 营收同比 | 26.9% | -3.7% |
| 净利润同比 | -22.2% | -3583.4% |
| 每股收益（稀释后） | $0.12 | $-10.78 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CSGPQDEL
| Q4 25 | $899.9M | — | ||
| Q3 25 | $833.6M | $699.9M | ||
| Q2 25 | $781.3M | $613.9M | ||
| Q1 25 | $732.2M | $692.8M | ||
| Q4 24 | $709.4M | $707.8M | ||
| Q3 24 | $692.6M | $727.1M | ||
| Q2 24 | $677.8M | $637.0M | ||
| Q1 24 | $656.4M | $711.0M |
净利润CSGPQDEL
| Q4 25 | $46.5M | — | ||
| Q3 25 | $-30.9M | $-733.0M | ||
| Q2 25 | $6.2M | $-255.4M | ||
| Q1 25 | $-14.8M | $-12.7M | ||
| Q4 24 | $59.8M | $-178.4M | ||
| Q3 24 | $53.0M | $-19.9M | ||
| Q2 24 | $19.2M | $-147.7M | ||
| Q1 24 | $6.7M | $-1.7B |
毛利率CSGPQDEL
| Q4 25 | 78.6% | — | ||
| Q3 25 | 79.3% | — | ||
| Q2 25 | 78.5% | — | ||
| Q1 25 | 79.1% | — | ||
| Q4 24 | 80.1% | — | ||
| Q3 24 | 79.7% | — | ||
| Q2 24 | 80.0% | — | ||
| Q1 24 | 78.5% | — |
营业利润率CSGPQDEL
| Q4 25 | 5.5% | — | ||
| Q3 25 | -6.1% | -100.7% | ||
| Q2 25 | -3.5% | -29.4% | ||
| Q1 25 | -5.8% | 4.7% | ||
| Q4 24 | 5.6% | -14.2% | ||
| Q3 24 | 3.4% | 2.1% | ||
| Q2 24 | -2.4% | -18.4% | ||
| Q1 24 | -6.5% | -247.3% |
净利率CSGPQDEL
| Q4 25 | 5.2% | — | ||
| Q3 25 | -3.7% | -104.7% | ||
| Q2 25 | 0.8% | -41.6% | ||
| Q1 25 | -2.0% | -1.8% | ||
| Q4 24 | 8.4% | -25.2% | ||
| Q3 24 | 7.7% | -2.7% | ||
| Q2 24 | 2.8% | -23.2% | ||
| Q1 24 | 1.0% | -239.9% |
每股收益（稀释后）CSGPQDEL
| Q4 25 | $0.12 | — | ||
| Q3 25 | $-0.07 | $-10.78 | ||
| Q2 25 | $0.01 | $-3.77 | ||
| Q1 25 | $-0.04 | $-0.19 | ||
| Q4 24 | $0.14 | $-2.54 | ||
| Q3 24 | $0.13 | $-0.30 | ||
| Q2 24 | $0.05 | $-2.20 | ||
| Q1 24 | $0.02 | $-25.50 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $1.6B | $98.1M |
| 总债务越低越好 | $140.0M | $2.5B |
| 股东权益账面价值 | $8.3B | $2.0B |
| 总资产 | $10.5B | $5.7B |
| 负债/权益比越低杠杆越低 | 0.02× | 1.23× |
8季度趋势，按日历期对齐
现金及短期投资CSGPQDEL
| Q4 25 | $1.6B | — | ||
| Q3 25 | $1.9B | $98.1M | ||
| Q2 25 | $3.6B | $151.7M | ||
| Q1 25 | $3.7B | $127.1M | ||
| Q4 24 | $4.7B | $98.3M | ||
| Q3 24 | — | $143.7M | ||
| Q2 24 | — | $107.0M | ||
| Q1 24 | — | $78.5M |
总债务CSGPQDEL
| Q4 25 | $140.0M | — | ||
| Q3 25 | $1.0B | $2.5B | ||
| Q2 25 | $1.0B | $2.1B | ||
| Q1 25 | $1.0B | $2.1B | ||
| Q4 24 | $1.0B | $2.1B | ||
| Q3 24 | $1.0B | $2.2B | ||
| Q2 24 | $1.0B | $2.2B | ||
| Q1 24 | $1.0B | $2.2B |
股东权益CSGPQDEL
| Q4 25 | $8.3B | — | ||
| Q3 25 | $8.6B | $2.0B | ||
| Q2 25 | $8.6B | $2.8B | ||
| Q1 25 | $8.6B | $3.0B | ||
| Q4 24 | $7.6B | $3.0B | ||
| Q3 24 | $7.5B | $3.2B | ||
| Q2 24 | $7.4B | $3.2B | ||
| Q1 24 | $7.3B | $3.3B |
总资产CSGPQDEL
| Q4 25 | $10.5B | — | ||
| Q3 25 | $10.8B | $5.7B | ||
| Q2 25 | $10.5B | $6.4B | ||
| Q1 25 | $10.4B | $6.5B | ||
| Q4 24 | $9.3B | $6.4B | ||
| Q3 24 | $9.1B | $6.8B | ||
| Q2 24 | $9.1B | $6.7B | ||
| Q1 24 | $9.0B | $6.7B |
负债/权益比CSGPQDEL
| Q4 25 | 0.02× | — | ||
| Q3 25 | 0.12× | 1.23× | ||
| Q2 25 | 0.12× | 0.74× | ||
| Q1 25 | 0.12× | 0.70× | ||
| Q4 24 | 0.13× | 0.72× | ||
| Q3 24 | 0.13× | 0.68× | ||
| Q2 24 | 0.14× | 0.70× | ||
| Q1 24 | 0.14× | 0.68× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $162.1M | $-45.5M |
| 自由现金流经营现金流 - 资本支出 | $101.3M | $-94.7M |
| 自由现金流率自由现金流/营收 | 11.3% | -13.5% |
| 资本支出强度资本支出/营收 | 6.8% | 7.0% |
| 现金转化率经营现金流/净利润 | 3.49× | — |
| 过去12个月自由现金流最近4个季度 | $123.0M | $-153.1M |
8季度趋势，按日历期对齐
经营现金流CSGPQDEL
| Q4 25 | $162.1M | — | ||
| Q3 25 | $68.2M | $-45.5M | ||
| Q2 25 | $146.5M | $-46.8M | ||
| Q1 25 | $53.2M | $65.6M | ||
| Q4 24 | $94.6M | $63.7M | ||
| Q3 24 | $100.3M | $117.9M | ||
| Q2 24 | $58.1M | $-97.9M | ||
| Q1 24 | $139.6M | $-700.0K |
自由现金流CSGPQDEL
| Q4 25 | $101.3M | — | ||
| Q3 25 | $-5.5M | $-94.7M | ||
| Q2 25 | $27.7M | $-84.3M | ||
| Q1 25 | $-500.0K | $9.4M | ||
| Q4 24 | $25.2M | $16.5M | ||
| Q3 24 | $40.2M | $71.4M | ||
| Q2 24 | $-14.7M | $-133.2M | ||
| Q1 24 | $-237.1M | $-66.8M |
自由现金流率CSGPQDEL
| Q4 25 | 11.3% | — | ||
| Q3 25 | -0.7% | -13.5% | ||
| Q2 25 | 3.5% | -13.7% | ||
| Q1 25 | -0.1% | 1.4% | ||
| Q4 24 | 3.6% | 2.3% | ||
| Q3 24 | 5.8% | 9.8% | ||
| Q2 24 | -2.2% | -20.9% | ||
| Q1 24 | -36.1% | -9.4% |
资本支出强度CSGPQDEL
| Q4 25 | 6.8% | — | ||
| Q3 25 | 8.8% | 7.0% | ||
| Q2 25 | 15.2% | 6.1% | ||
| Q1 25 | 7.3% | 8.1% | ||
| Q4 24 | 9.8% | 6.7% | ||
| Q3 24 | 8.7% | 6.4% | ||
| Q2 24 | 10.7% | 5.5% | ||
| Q1 24 | 57.4% | 9.3% |
现金转化率CSGPQDEL
| Q4 25 | 3.49× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 23.63× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.58× | — | ||
| Q3 24 | 1.89× | — | ||
| Q2 24 | 3.03× | — | ||
| Q1 24 | 20.84× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CSGP
| Co Star | $503.8M | 56% |
| Other | $283.0M | 31% |
| Loop Net | $94.7M | 11% |
QDEL
| Labs | $373.8M | 53% |
| Point Of Care | $164.6M | 24% |
| Immunohematology | $142.0M | 20% |
| Donor Screening | $14.7M | 2% |
| Molecular Diagnostics | $4.8M | 1% |
| Collaborative Arrangement Transaction With Party To Collaborative Arrangement | $2.1M | 0% |
